Brief: Sellas Life Sciences Announces Positive Recommendation From Data Monitoring Committee Of Phase 3 Trial In Acute Myeloid Leukemia

Sellas Life Sciences

17/06/2024 14:23

June 17 (Reuters) - Sellas Life Sciences Group Inc
 SLS.O :
    * SELLAS LIFE SCIENCES ANNOUNCES POSITIVE RECOMMENDATION
FROM THE
INDEPENDENT DATA MONITORING COMMITTEE OF THE PHASE 3 REGAL TRIAL
IN ACUTE MYELOID LEUKEMIA
    * SELLAS LIFE SCIENCES GROUP INC - INTERIM ANALYSIS
ANTICIPATED BY
Q4 2024
    * SELLAS LIFE SCIENCES GROUP INC: NO SAFETY OR FUTILITY
CONCERNS
WERE RAISED BASED ON EFFICACY AND SAFETY ASSESSMENT OF ALL REGAL
PATIENTS
    * SELLAS LIFE SCIENCES GROUP INC - INDEPENDENT DATA
MONITORING
COMMITTEE (IDMC) RECOMMENDS CONTINUATION OF PHASE 3 REGAL TRIAL
WITHOUT ANY MODIFICATIONS

Source text for Eikon:  ID:nGNX1g8F3b 
Further company coverage:  SLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))